1. Home
  2. AKTX vs RAY Comparison

AKTX vs RAY Comparison

Compare AKTX & RAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$11.04

Market Cap

15.4M

Sector

Health Care

ML Signal

HOLD

Logo Raytech Holding Limited Ordinary Shares

RAY

Raytech Holding Limited Ordinary Shares

HOLD

Current Price

$2.84

Market Cap

15.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKTX
RAY
Founded
N/A
1993
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Electronics/Appliances
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
15.9M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
AKTX
RAY
Price
$11.04
$2.84
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$33.50
N/A
AVG Volume (30 Days)
78.3K
5.7K
Earning Date
05-14-2026
07-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.84
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.15
52 Week High
$29.32
$5.99

Technical Indicators

Market Signals
Indicator
AKTX
RAY
Relative Strength Index (RSI) 59.30 51.50
Support Level $9.20 $2.43
Resistance Level $15.50 $3.05
Average True Range (ATR) 1.19 0.09
MACD 0.28 0.00
Stochastic Oscillator 69.76 70.15

Price Performance

Historical Comparison
AKTX
RAY

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About RAY Raytech Holding Limited Ordinary Shares

Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Mens Care and Womens Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; nail care series and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, and others.

Share on Social Networks: